Journey Medical Corporation (DERM) Stock

Journey Medical Corporation (DERM) is a Healthcare stock trading at $6.20 (as of 2026-06-18), with a market capitalization of $172.29M and a trailing P/E of -17.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Journey Medical Corporation develops and commercializes pharmaceutical products for dermatological conditions in the United States. Its portfolio includes Qbrexza for primary axillary hyperhidrosis, oral therapies such as Accutane, Targadox, and Ximino for acne, and topical Exelderm, along with sales of doxycycline and minocycline oral products and sulconazole nitrate topical products.

Valuation — source: SEC EDGAR (first-party)
Price$6.20
Market Cap$172.29M
P/E Ratio-17.1
Price / Book5.61
Price / Sales2.68
DCF Value (model)$-8.69
DCF Upside vs Price-240.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$61.86M
Net Margin-18.5%
Return on Equity-31.1%
Debt / Equity0.82
Current Ratio1.72
Revenue Growth (YoY)21.5%
EPS Growth (YoY)-55.6%
Financial Health — source: SEC EDGAR
Altman Z-Score0.74 (distress)
Piotroski F-Score4/9 (moderate)
Valuation vs Sector & Industry
Stock P/E-17.1
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-182.0%
vs Industry-200.7%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock Fund Advisors ($45.12M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOClaude Maraoui
Employees41
CountryUS
IPO Date2021-11-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Nuvectis Pharma, Inc. (NVCT)
  • Kalaris Therapeutics Inc (KLRS)
  • Cardiff Oncology, Inc. (CRDF)
  • Sagimet Biosciences Inc. (SGMT)
  • Climb Bio, Inc. (CLYM)
  • Cartesian Therapeutics, Inc. (RNAC)
  • Quince Therapeutics, Inc. (QNCX)
  • C4 Therapeutics, Inc. (CCCC)
DERM earnings history · DERM institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.